An Open-Label, Randomized, 4-Period, 4-Treatment, Crossover, Single-Center, Single-Dose Bioavailability Study With Alternate Methods of Administration of Crushed Naloxegol Tablets, 25 mg and of a Naloxegol Solution Formulation, 25 mg, Compared to Whole Naloxegol Tablets, 25 mg, in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 16 Mar 2017
At a glance
- Drugs Naloxegol (Primary)
- Indications Constipation
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 27 Jul 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 22 Jun 2015 Status changed from not yet recruiting to recruiting as per ClinicalTrials.gov record.
- 21 May 2015 New trial record